![](https://partners4access.com/wp-content/uploads/2021/06/FDA-image-2-e1624032977497-300x169.jpeg)
Blogs
FDA stokes controversy with Alzheimer’s drug approval – what will it mean?
By Max Rex, Consultant Email: [email protected] On Monday 7th June, the FDA approved aducanumab, the first new treatment for Alzheimer’s in 18 years. Aducanumab, manufactured